Prevalence and Risk Factors of Hyperuricemia in Patients with Chronic Kidney Disease and Non-Alcoholic Fatty Liver

References

• Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006;332(7541):563–564. doi:10.1136/bmj.332.7541.563
   PubMed Web of Science ®Google Scholar
• Bouya S, Balouchi A, Rafiemanesh H, Hesaraki M. Prevalence of chronic kidney disease in Iranian general population: a meta-analysis and systematic review. Ther Apher Dial. 2018;22(6):594–599. doi:10.1111/1744-9987.12716
   Web of Science ®Google Scholar
• Ndrepepa G. Uric acid and cardiovascular disease. Clinica Chimica Acta. 2018;484:150–163. doi:10.1016/j.cca.2018.05.046
   PubMed Web of Science ®Google Scholar
• Oh TR, Choi HS, Kim CS, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019;9(1):1–9. doi:10.1038/s41598-019-43241-3
   PubMed Web of Science ®Google Scholar
• Li L-X, Dong X-H, Li M-F, et al. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. J Hypertens. 2015;33(3):482. doi:10.1097/HJH.0000000000000417
   PubMed Web of Science ®Google Scholar
• Golmohammadi S, Almasi A, Manouchehri M, et al. Allopurinol against progression of chronic kidney disease. Iran J Kidney Dis. 2017;11(4):286–293.
   PubMed Web of Science ®Google Scholar
• Yu S, Yang H, Guo X, et al. Prevalence of hyperuricemia and its correlates in rural Northeast Chinese population: from lifestyle risk factors to metabolic comorbidities. Clin Rheumatol. 2016;35(5):1207–1215. doi:10.1007/s10067-015-3051-6
   PubMed Web of Science ®Google Scholar
• Huang Q, Yu J, Zhang X, et al. Association of the serum uric acid level with liver histology in biopsy‑proven non-alcoholic fatty liver disease. Biomed Rep. 2016;5(2):188–192. doi:10.3892/br.2016.698
   Google Scholar
• Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016;22(16):4079. doi:10.3748/wjg.v22.i16.4079
   PubMed Web of Science ®Google Scholar
• Bashiri H, Bozorgomid A, Shojaeimotlagh V. Efficacy of Hijamat (wet cupping therapy) in Iranian patients with nonalcoholic fatty liver disease: a controlled clinical trial . Turk J Med Sci. 2020;50(2):354–359. doi:10.3906/sag-1907-82
   Web of Science ®Google Scholar
• Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258–1269. doi:10.2337/db10-0916
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Milic S, Wensveen TT, et al. Nonalcoholic fatty liver disease – a multisystem disease? World J Gastroenterol. 2016;22(43):9488. doi:10.3748/wjg.v22.i43.9488
   Web of Science ®Google Scholar
• Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64–76. doi:10.1016/j.metabol.2017.11.003
   PubMed Web of Science ®Google Scholar
• Golmohamadi S, Omrani HR, Asadi N, et al. Non-alcoholic fatty liver disease and associated risk factors among hemodialysis patients. World Fam Med J. 2018;99(5804):1–5.
   Google Scholar
• Song P, Wang H, Xia W, et al. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 2018;8(1):1–9. doi:10.1038/s41598-017-17765-5
   PubMed Web of Science ®Google Scholar
• Zhao -C-C, Wang A-P, Li L-X, et al. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications. 2016;30(6):1074–1080. doi:10.1016/j.jdiacomp.2016.04.017
   Web of Science ®Google Scholar
• Uaratanawong S, Suraamornkul S, Angkeaw S, et al. Prevalence of hyperuricemia in Bangkok population. Clin Rheumatol. 2011;30(7):887–893. doi:10.1007/s10067-011-1699-0
   PubMed Web of Science ®Google Scholar
• Kim Y, Kang J, Kim G-T. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 2018;37(9):2529–2538. doi:10.1007/s10067-018-4130-2
   PubMed Web of Science ®Google Scholar
• Yano Y, Fujimoto S, Asahi K, et al. Prevalence of chronic kidney disease in China. Lancet. 2012;380(9838):213–214. doi:10.1016/S0140-6736(12)61209-4
   PubMed Web of Science ®Google Scholar
• Sari I, Akar S, Pakoz B, et al. Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheum Int. 2009;29(8):869–874. doi:10.1007/s00296-008-0806-2
   PubMed Web of Science ®Google Scholar
• Sorensen LB, Levinson DJ. Origin and extrarenal elimination of uric acid in man. Nephron. 1975;14(1):7–20. doi:10.1159/000180432
   PubMed Web of Science ®Google Scholar
• Marangella M. Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol. 2005;147:132–148. doi:10.1159/000082551
   PubMed Web of Science ®Google Scholar
• Hou Y-L, Yang X-L, Wang C-X, et al. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18(1):81. doi:10.1186/s12944-019-1031-6
   PubMed Web of Science ®Google Scholar
• Ni Q, Lu X, Chen C, et al. Risk factors for the development of hyperuricemia: a STROBE-compliant cross-sectional and longitudinal study. Medicine. 2019;98(42):e17597. doi:10.1097/MD.0000000000017597
   PubMed Web of Science ®Google Scholar
• Guan S, Tang Z, Fang X, et al. Prevalence of hyperuricemia among Beijing post-menopausal women in 10 years. Arch Gerontol Geriatr. 2016;64:162–166. doi:10.1016/j.archger.2016.02.002
   PubMed Web of Science ®Google Scholar
• Ali N, Perveen R, Rahman S, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: a study on Bangladeshi adults. PLoS One. 2018;13(11):e0206850. doi:10.1371/journal.pone.0206850
   PubMed Web of Science ®Google Scholar
• Villegas R, Xiang Y-B, Elasy T, et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutr Metab Cardiovasc Dis. 2012;22(5):409–416. doi:10.1016/j.numecd.2010.07.012
   PubMed Web of Science ®Google Scholar
• Keenan T, Blaha MJ, Nasir K, et al. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol. 2012;110(12):1787–1792. doi:10.1016/j.amjcard.2012.08.012
   Web of Science ®Google Scholar
• Jung J-Y, Choi Y, Suh C-H, et al. Effect of fenofibrate on uric acid level in patients with gout. Sci Rep. 2018;8(1):1–9. doi:10.1038/s41598-018-35175-z
   Web of Science ®Google Scholar
• Bartlett J, Predazzi IM, Williams SM, et al. Is isolated low high-density lipoprotein cholesterol a cardiovascular disease risk factor? New insights from the Framingham offspring study. Circ Cardiovasc Interv. 2016;9(3):206–212. doi:10.1161/CIRCOUTCOMES.115.002436
   Web of Science ®Google Scholar
• Wu J, Lei G, Wang X, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget. 2017;8(46):80688. doi:10.18632/oncotarget.21079
   PubMedGoogle Scholar
• Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016;11(1):54. doi:10.15420/ecr.2016:4:2
   PubMed Web of Science ®Google Scholar
• Shojaeimotlagh V, Lazari N, Ghalenoee M, et al. Relationship between metabolic syndrome and depression in elderlies with cardiovascular disease. Iran J Nurs. 2015;27(92):65–72. doi:10.29252/ijn.27.92.65
   Google Scholar